Combo of PDE5i, Nitrates Increases Cardiovascular Morbidity, Mortality in Stable CAD
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 16, 2024 -- For men with stable coronary artery disease receiving nitrate medication, the use of phosphodiesterase-5 inhibitor (PDE5i) treatment for erectile dysfunction is associated with increased cardiovascular morbidity and mortality, according to a study published in the Jan. 23 issue of the Journal of the American College of Cardiology.
Ylva Trolle Lagerros, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues used data from the Swedish Patient Register and the Prescribed Drug Register to examine the association between PDE5i treatment and cardiovascular outcomes in men with stable coronary artery disease treated with nitrate medication. Exposure was defined as two or more dispensed prescriptions of PDE5i.
The analysis included 55,777 men who were treated with nitrates and 5,710 men treated with nitrates and a PDE5i. The researchers found that combined use of PDE5i treatment with nitrates was associated with increased mortality, cardiovascular mortality, noncardiovascular mortality, myocardial infarction, heart failure, cardiac revascularization, and major cardiovascular events (hazard ratios, 1.39, 1.34, 1.40, 1.72, 1.67, 1.95, and 1.70, respectively).
"Our goal is to underscore the need for careful patient-centered consideration before prescribing PDE5i medication to men receiving nitrate treatment," senior author Daniel Peter Andersson, M.D., Ph.D., from Stockholm University, said in a statement. "Furthermore, it justifies our efforts for continued research into the ambiguous effects of erectile dysfunction drugs on men with cardiovascular disease."
One author disclosed ties to the pharmaceutical industry.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Cardiorespiratory Fitness Cuts Risk for Poor Cardiovascular Disease Outcomes
WEDNESDAY, May 8, 2024 -- There is consistent evidence that high cardiorespiratory fitness (CRF) is strongly associated with a lower risk for a variety of cardiovascular disease...
Long-Term Risk for MACE Increased for Children With Hypertension
TUESDAY, May 7, 2024 -- The long-term risk for major adverse cardiac events (MACE) is increased for children diagnosed with hypertension, according to a study published online May...
A-Fib Patients Younger Than 65 Face Heightened Risk for Heart-Related Hospitalization
TUESDAY, May 7, 2024 -- Patients younger than 65 years with atrial fibrillation (AF) have a significant burden of risk factors and comorbidities, as well as heightened risk for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.